Lantern Pharma Inc.
Data quality: 83%
LTRN
Nasdaq
Manufacturing
Chemicals
$1.90
▼
$0.04
(-2.06%)
Mkt Cap: 21.38 M
Price
$1.90
Mkt Cap
21.38 M
Day Range
$1.85 — $1.97
52-Week Range
$1.11 — $5.74
Volume
246,274
Open $1.94
50D / 200D Avg
$2.55
25.50% below
50D / 200D Avg
$3.53
46.16% below
Quick Summary
Key Takeaways
Negative free cash flow of -15.68 M
Growth
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Quality
Return on Equity
-154.86%
Below sector avg (-53.41%)
ROIC-128.40%
Net MarginN/A
Op. MarginN/A
Safety
Debt / Equity
N/A
Current Ratio3.33
Interest CoverageN/A
Valuation
PE (TTM)
-1.25
Above sector avg (-1.48)
P/B Ratio2.23
EV/EBITDAN/A
Dividend YieldN/A
Price History
Financial Trends
Peer Comparison
vs Manufacturing sector median (1364 peers)
Peer Comparison
vs Manufacturing sector median (1364 peers)| Metric | Stock | Sector Median |
|---|---|---|
| P/E | -1.3 | -1.5 |
| P/B | 2.2 | 1.6 |
| ROE % | -154.9 | -53.4 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.8 |
| D/E | — | 0.3 |
ETFs Holding This Stock
0.70% weight
All Fundamental Metrics
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
| Profitability | |||
| Revenue (TTM) | N/A | Net Income (TTM) | -17.12 M |
| ROE | -154.86% | ROA | -110.28% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -15.68 M |
| ROIC | -128.40% | FCF Growth (3Y) | N/A |
| Safety | |||
| Debt / Equity | N/A | Current Ratio | 3.33 |
| Interest Coverage | N/A | Asset Turnover | N/A |
| Working Capital | 9.42 M | Tangible Book Value | 9.59 M |
| Dividends | |||
| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
| Valuation | |||
| P/E Ratio | -1.25 | Forward P/E | N/A |
| P/B Ratio | 2.23 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -73.32% | ||
| Market Cap | 21.38 M | Enterprise Value | 12.99 M |
| Per Share | |||
| EPS (Diluted TTM) | -1.57 | Revenue / Share | N/A |
| FCF / Share | -1.39 | OCF / Share | -1.39 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
| Efficiency | |||
| CapEx / Revenue | N/A | FCF Conversion | 91.58% |
| SBC-Adj. FCF | -16.31 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -17.12 M | -20.78 M | -15.96 M | -14.26 M | -12.36 M |
| EPS (Diluted) | -1.57 | -1.93 | -1.47 | — | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -17.98 M | -22.22 M | -17.88 M | -14.43 M | — |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 11.51 M | 16.13 M | 11.89 M | 8.60 M | 7.57 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | 17,280.0 | 17,282.0 | 14,615.0 | 10,081.0 | 6,761.0 |
| Interest Expense | — | — | — | — | — |
| Income Tax | — | — | — | — | — |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 11.04 M | 25.57 M | 43.65 M | 58.84 M | 73.95 M |
| Total Liabilities | 4.50 M | 4.38 M | 2.74 M | 2.80 M | 2.38 M |
| Shareholders' Equity | 6.53 M | 21.19 M | 40.91 M | 56.04 M | 71.57 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 4.42 M | 7.51 M | 21.94 M | 37.20 M | 51.52 M |
| Current Assets | 10.80 M | 25.25 M | 43.34 M | 58.72 M | 72.72 M |
| Current Liabilities | 4.50 M | 4.33 M | 2.68 M | 2.80 M | 2.33 M |
{"event":"ticker_viewed","properties":{"ticker":"LTRN","listing_kind":"stock","pathname":"/stocks/ltrn","exchange":"Nasdaq","country":"US"}}